FDA Drug Recalls

Recalls / Class II

Class IID-0632-2020

Product

RANITIDINE TABLETS, USP 150mg, 10,000-count bag, Country of Origin: INDIA NDC 62207-773-32

Brand name
Ranitidine
Generic name
Ranitidine
Active ingredient
Ranitidine Hydrochloride
Route
Oral
NDCs
62207-773, 62207-774
FDA application
ANDA210243
Affected lot / code info
7730001A, 7730002A, 7730003A, 7730004A, 7730005A, 7730006A, 7730007A, 7730008A, 7730009A, 7730010A, 7730011A and 7730012A

Why it was recalled

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Recalling firm

Firm
Granules India Limited
Manufacturer
Granules India Ltd
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
Plot No. 160/A, 161/E, 162 and 174/A, Gagillapur Village, Qutbullapur Mandal, Ranga Redd, N/A N/A, India

Distribution

Quantity
23,090,000 tablets
Distribution pattern
OR, NY, NJ

Timeline

Recall initiated
2019-12-13
FDA classified
2019-12-29
Posted by FDA
2020-01-08
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0632-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Ranitidine · FDA Drug Recalls